製品# | サイズ | 数量 | 価格 | 在庫 |
---|---|---|---|---|
86791T | 1 Kit (9 x 20 microliters) |
|
Product Includes | Quantity | Applications | Reactivity | MW(kDa) | Isotype |
---|---|---|---|---|---|
CD14 (D7A2T) Rabbit mAb (IHC Formulated) 75181 | 20 µl |
|
H Mk | Rabbit IgG | |
CD11b/ITGAM (D6X1N) Rabbit mAb 49420 | 20 µl |
|
H Mk | 170 | Rabbit IgG |
CD68 (D4B9C) XP® Rabbit mAb 76437 | 20 µl |
|
H Mk | Rabbit IgG | |
CD163 (D6U1J) Rabbit mAb 93498 | 20 µl |
|
H Mk | 160, 170 | Rabbit IgG |
CD206/MRC1 (E2L9N) Rabbit mAb 91992 | 20 µl |
|
H | 190-250 | Rabbit IgG |
CSF-1R/M-CSF-R (E4T8Z) Rabbit mAb 28917 | 20 µl |
|
H | 140-200 | Rabbit IgG |
Arginase-1 (D4E3M™) XP® Rabbit mAb 93668 | 20 µl |
|
H M R | 40 | Rabbit IgG |
MHC Class II (LGII-612.14) Mouse mAb 68258 | 20 µl |
|
H | 25-35, 50-65 | Mouse IgG1 |
CD15/SSEA1 (MC480) Mouse mAb 4744 | 20 µl |
|
H M | N/A | Mouse IgM |
製品情報
Monoclonal antibodies are produced by immunizing animals with synthetic peptides corresponding to residues surrounding Pro319 of human CD14 protein or Val47 of human arginase-1 protein, or with recombinant protein specific to human CD68 protein, human CD163 protein, human CD206/MRC1 protein, the carboxy terminus of human M-CSF receptor protein, or the amino terminus of human CD11b/ITGAM protein. CD15/SSEA1 (MC480) Mouse mAb is produced by immunizing animals with F9 teratoma cells (X-irradiated). MHC Class II (LGII-612.14) Mouse mAb is produced by immunizing animals with cultured human B lymphoid cells treated with IFN-gamma.
A combination of multiple biomarkers are required to characterize the phenotype of myeloid cell lineages. Cluster of differentiation molecule 14 (CD14) is a leucine-rich repeat-containing pattern recognition receptor with expression largely restricted to the monocyte/macrophage cell lineage (1), but can be unregulated on polymorphonuclear as well as nonmyeloid cells such as B cells and gingival fibroblasts (2,3). CD11b (Integrin alpha M or ITGAM) is a transmembrane protein forming heterodimers that are composed of α and β subunits (4). CD11b is expressed by, and commonly used as a marker for myeloid lineage cells, including neutrophils, monocytes, macrophages, dendritic cells, and microglia (5), but has also been detected on a subset of B cells (6-8). CD68 (macrosialin) is a heavily glycosylated transmembrane protein that is expressed by and commonly used as a marker for monocytes and macrophages (9,10), but there is also evidence of non-myeloid cell expression (11). The CD15 carbohydrate epitope is preferentially expressed in mature human neutrophils, monocytes, and all myeloid cells from the promyelocyte stage onwards, making it a useful cell surface marker (12-14). It is also expressed in some tissues, such as epithelial cells of intestinal tissues (15,16), and in certain neurons and glial cells in the central nervous system (17).
CD163 is a transmembrane scavenger receptor expressed on the macrophage surface. It has 9 B-type SRCR extracellular domains mediating serum haptoglobin clearing/endocytosis, pathogen binding and signal transduction, and calcium binding (18,19). The mannose receptor (CD206/MR/CLEC13D/MMR/MRC1/Macrophage mannose receptor 1) is an endocytic receptor expressed by populations of dendritic cells, macrophages, and nonvascular endothelium (20). CD206/MRC1 receptor functions include a role in antigen cross-presentation, clearance of endogenous proteins, pathogen detection and trafficking through lymphatic vessels (21-24). Macrophage-colony stimulating factor (M-CSF, CSF-1) receptor is an integral membrane tyrosine kinase encoded by the c-fms proto-oncogene. M-CSF receptor is expressed in monocytes (macrophages and their progenitors) and drives growth and development of this blood cell lineage (25,26). CD163, CD206, and M-CSF receptors are used as surface markers of M2 type macrophages, including M2 type tumor associated macrophages (TAMs), which facilitate cancer progression by secreting cytokines to promote angiogenesis, immunosuppression, and metastasis (20,27,28). Arginase-1 catalyzes the final step of the urea cycle converting L-arginine to L-ornithine and urea (29). Myeloid-derived suppressor cells express high levels of arginase-1, increasing the catabolism of L-arginine resulting in L-arginine depletion in the inflammatory microenvironment of cancer. The reduced availability of L-arginine suppresses T cell proliferation and function and thus contributes to tumor progression (30,31).
Major histocompatibility complex class II (MHC class II) molecules are heterodimeric, transmembrane glycoproteins expressed on the surface of antigen-presenting cells such as macrophages, dendritic cells, and B cells. Expression can also be induced through interferon-γ signaling (32). Prior to being displayed on the cell membrane, MHC class II molecules are loaded with exogenous peptide antigens approximately 15-24 amino acids in length that were derived from endocytosed extracellular proteins digested in the lysosome. Antigen-presentation through MHC class II is required for T cell activation during the immune response to extracellular pathogens (33). High expression of MHC class II on myeloid cell lineages is used as a surface marker of M1 type macrophages, including M1 type TAMs, which can assist in tumor eradication by secreting cytokines to activate anti-tumor immune responses, and inhibit angiogenesis and metastasis (27,28).
Explore pathways related to this product.
法的な権限を与えられたCSTの担当者が署名した書面によって別途明示的に合意された場合を除き、 CST、その関連会社または代理店が提供する製品には以下の条件が適用されます。お客様が定める条件でここに定められた条件に含まれるものを超えるもの、 または、ここに定められた条件と異なるものは、法的な権限を与えられたCSTの担当者が別途書面にて受諾した場合を除き、拒絶され、 いかなる効力も効果も有しません。
研究専用 (For Research Use Only) またはこれに類似する表示がされた製品は、 いかなる目的についても FDA または外国もしくは国内のその他の規制機関により承認、認可または許可を受けていません。 お客様は製品を診断もしくは治療目的で使用してはならず、また、製品に表示された内容に違反する方法で使用してはなりません。 CST が販売または使用許諾する製品は、エンドユーザーであるお客様に対し、使途を研究および開発のみに限定して提供されるものです。 診断、予防もしくは治療目的で製品を使用することまたは製品を再販売 (単独であるか他の製品等の一部であるかを問いません) もしくはその他の商業的利用の目的で購入することについては、CST から別途許諾を得る必要があります。 お客様は以下の事項を遵守しなければなりません。(a) CST の製品 (単独であるか他の資材と一緒であるかを問いません) を販売、使用許諾、貸与、寄付もしくはその他の態様で第三者に譲渡したり使用させたりしてはなりません。また、商用の製品を製造するために CST の製品を使用してはなりません。(b) 複製、改変、リバースエンジニアリング、逆コンパイル、 分解または他の方法により製品の構造または技術を解明しようとしてはなりません。また、 CST の製品またはサービスと競合する製品またはサービスを開発する目的で CST の製品を使用してはなりません。(c) CST の製品の商標、商号、ロゴ、特許または著作権に関する通知または表示を除去したり改変したりしてはなりません。(d) CST の製品をCST 製品販売条件(CST’s Product Terms of Sale) および該当する書面のみに従って使用しなければなりません。(e) CST の製品に関連してお客様が使用する第三者の製品またはサービスに関する使用許諾条件、 サービス提供条件またはこれに類する合意事項を遵守しなければなりません。